Pharmacoeconomic review report : Nusinersen (Spinraza) (Biogen Canada Inc.)

Pharmacoeconomic review report Nusinersen (Spinraza) (Biogen Canada Inc.)

Spinal muscular atrophy (SMA) is a severe neuromuscular disease and is the leading genetic cause of infant death. It is characterized by the degeneration of alpha motor neurons in the anterior horn of the spinal cord, leading to progressive muscle weakness. The most common form of SMA, 5q SMA, makes...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health 2018.
Colección:Common drug review clinical review report.
Materias:
Drugs > Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268706719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of Identified Limitations and Key Results
  • Conclusions
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's PE submission
  • Manufacturer's Base case
  • Summary of Manufacturer's Sensitivity Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Issues for Consideration
  • Patient Input
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Additional Information
  • Appendix 3. Summary of Other HTA Reviews of Drug
  • Appendix 4. Reviewer Worksheets
  • References.

Ejemplares similares